ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,861 to 2,880 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR)94 of 1,282

82 of 1,291

1.0 points

-1.0 to 3.0

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)67 of 1,282

53 of 1,291

1.1 points

-0.5 to 2.8

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)23 of 1,282

11 of 1,291

0.9 points

0.0 to 1.9

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)77 of 1,282

64 of 1,291

1.0 points

-0.7 to 2.8

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI74 of 1,282

64 of 1,291

0.8 points

-0.9 to 2.6

2,573NCT02173379

Absorb IV Randomized Controlled Trial

Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): deaths from any cause9 of 1,773

1 of 796

0.4 points

-0.2 to 0.8

2,569NCT02118584

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): serious adverse events373 of 1,773

2 of 796

20.8 points

18.8 to 22.8

2,569NCT02118584

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

Dabigatran 150 mg vs Warfarin: serious adverse events156 of 1,280

153 of 1,288

0.3 points

-2.2 to 2.8

2,568NCT00680186

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography57 of 1,278

64 of 1,284

-0.5 points

-2.2 to 1.1

2,562NCT02173379

Absorb IV Randomized Controlled Trial

Ferric Carboxymaltose (FCM) vs Iron Sucrose (Venofer): Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.175 of 1,276

156 of 1,285

1.6 points

-1.0 to 4.2

2,561NCT00981045

Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function

Ferric Carboxymaltose (FCM) vs Iron Sucrose (Venofer): serious adverse events202 of 1,276

197 of 1,285

0.5 points

-2.3 to 3.3

2,561NCT00981045

Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function

Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR)110 of 1,264

97 of 1,279

1.1 points

-1.0 to 3.3

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)19 of 1,264

16 of 1,279

0.3 points

-0.7 to 1.2

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)33 of 1,264

15 of 1,279

1.4 points

0.4 to 2.6

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)90 of 1,264

71 of 1,279

1.6 points

-0.3 to 3.5

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI)75 of 1,264

62 of 1,279

1.1 points

-0.7 to 2.9

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Rehospitalization227 of 1,265

237 of 1,278

-0.6 points

-3.6 to 2.4

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)101 of 1,264

86 of 1,279

1.3 points

-0.8 to 3.3

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR)32 of 1,264

15 of 1,279

1.4 points

0.3 to 2.5

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR19 of 1,264

16 of 1,279

0.3 points

-0.7 to 1.2

2,543NCT02173379

Absorb IV Randomized Controlled Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=144"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=144

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02173379-ac93bf52",
        "title": "Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR)",
        "summary": "94 of 1282 against 82 of 1291; risk difference 1.0 points, 95% interval -1.0 to 3.0; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-ac93bf52",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2573,
        "risk_difference": {
          "value": 0.009806279160539,
          "lower": -0.009793787780965221,
          "upper": 0.02950306763962557
        },
        "group_1": "94 of 1,282",
        "group_2": "82 of 1,291",
        "difference": "1.0 points",
        "interval": "-1.0 to 3.0",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      },
      {
        "id": "NCT02173379-af0992ab",
        "title": "Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)",
        "summary": "67 of 1282 against 53 of 1291; risk difference 1.1 points, 95% interval -0.5 to 2.8; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-af0992ab",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2573,
        "risk_difference": {
          "value": 0.011208643543263029,
          "lower": -0.005191898163230152,
          "upper": 0.02779572397084943
        },
        "group_1": "67 of 1,282",
        "group_2": "53 of 1,291",
        "difference": "1.1 points",
        "interval": "-0.5 to 2.8",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=145",
  "request_id": "cUoeKDj-gq_3H5K7"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?